Macular Degeneration Treatment Market Size, Share | 2032

Report Description

Macular Degeneration Treatment Market Outlook 2032

The global macular degeneration treatment market size was USD 13.8 Billion in 2023 and is likely to reach USD 27.2 Billion by 2032, expanding at a CAGR of 7.9% during 2024–2032. The market growth is attributed to the ­­increasing aging population and increasing public awareness initiatives across the globe.

Macular degeneration, also known as age-related macular degeneration (AMD), is a progressive eye condition affecting the macula, the central retina responsible for sharp vision. It is a leading cause of vision loss and blindness in older adults. There are two main types, dry AMD, which accounts for 85-90% of cases, and wet AMD, which accounts for most severe vision loss. Dry AMD occurs when drusen accumulates beneath the retina, causing deterioration and difficulty with tasks such as reading and driving.

There is a growing focus on targeted therapies, particularly anti-VEGF (vascular endothelial growth factor) drugs, which have revolutionized the treatment of wet age-related macular degeneration (AMD). These drugs are administered through intravitreal injections and work by inhibiting abnormal blood vessel growth in the retina, thereby preserving vision.

Get Free Sample Report

Impact of Artificial Intelligence (AI) in the Macular Degeneration Treatment Market

Early detection and diagnosis with AI algorithms analyze vast amounts of retinal imaging data to detect subtle changes indicative of macular degradation at early detection. The algorithms identify specific biomarkers or patterns not easily discernible to the human eye, enabling early diagnosis and intervention.

A personalized treatment generated by AI through patient data, including genetic information, medical history, and imaging results to tailor treatment. AI contributes to precision medicine approaches, optimizing therapeutic outcomes while minimizing adverse effects by identifying patient-specific risk factors and predicting treatment response.

Macular Degeneration Treatment Market Dynamics

Get Free Sample Report

Major Drivers

Increasing aging population is raising the demand for macular degradation treatment and boosting the market. AMD is common in individuals over the age of 50, and the demand for macular degeneration treatments rises with the aging population.

Advancements in the treatment such as optical coherence tomography (OCT) and photography, aiding the early monitoring and detection of macular degradation, are driving the market.  Additionally, innovations in treatment modalities such as anti-VEGF therapies and sustained-release drug delivery systems improve efficacy and patient outcomes.

Increasing public awareness initiatives by healthcare organizations, patient advocacy groups, and pharmaceutical companies is propelling the global market. This help educate individuals about the importance of regular eye exams and early detection of macular degeneration. Increased awareness leads to high rates of diagnosis and treatment initiation.

Existing Restraints

High cost of treatment of macular degradation, particularly anti-VEGF therapies, is restraining the market. This high cost of treatment limits the accessibility for patients, and is leading to underutilization of effective therapies, especially in the low-income nations.

Availability of limited treatment options for treating certain types of macular degradation is hindering the market. The lack of effective treatments for certain subtypes of the disease hampers market and leaves patients with unmet medical needs.

Emerging Opportunities

Advancements in the gene therapy holds a promising treatment strategy for macular degradation during the forecast period. This particularly addresses the genetic risk factors. Gene-based approaches aim to correct underlying genetic mutations or modulate gene expression to prevent or slow disease progression.

Innovation in the drug delivery system such as sustainable release implants and nanotechnological interventions is offering opportunities in the global market. These delivery platforms provide sustained release of therapeutic agents, reducing the frequency of injections and improving patient compliance.

Scope of the Macular Degeneration Treatment Market Report

The market report includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Macular Degeneration Treatment Market Segment Insights

Type Segment Analysis

Based on type, the macular degeneration treatment market is divided into dry age-related macular degeneration and wet age-related macular degeneration. The wet age-related macular degeneration segment is expected to expand at a significant growth rate during the projection period, due to increasing geriatric population and growing burden of wet age-related macular degradation. Moreover, the increasing product launch and rising investments in R&D activities is expected to boost the market in the coming years. For instance,

• In November 2022, CLS-AX demonstrated positive results in Phase 1 and 2 OASIS clinical trial in neovascular wet age-related macular degradation. CLS-AX is also marketed as Axitinib injectable suspension. The trail met its primary endpoint by demonstrating a positive safety profile in 27 participants in four cohorts at all doses and time points.
  

  Get Free Sample Report
  

Stage of Disease Segment Analysis

On the basis of stage of disease, the global market is segregated into early-stage AMD, intermediate AMD, and late-stage AMD. The late-stage AMD segment is anticipated to register a considerable CAGR in the coming years. Though not all cases of early AMD advance to late AMD, visual loss associated to macular degeneration peaks in late-stage AMD. The two distinct forms of late-stage AMD are neovascular AMD (also called wet AMD/nvAMD) and geographic atrophy (also called Dry AMD).

The introduction of anti-vascular endothelial growth factor (anti-VEGF) therapies has revolutionized the management of wet AMD, leading to enhanced visual outcomes and improved quality of life for patients. The availability of effective treatments encourages increasing number of patients to seek medical intervention, driving the segment.

Treatment Type Segment Analysis

On the basis of treatment type, the macular degeneration treatment market is segmented into drug, devices, and surgery. The drug segment is expected to register a robust growth rate during the forecast period, due to high availability of therapies such as anti-VEGF (vascular endothelial growth factor injection.

The device segment is expected to rise significantly during the forecast period, due to the availability of various device such as, implantable miniature telescope or retinal prostheses are used in specific conditions. Devices for macular degeneration treatment encompass a variety of technologies designed to assist individuals with vision impairment caused by the disease, propelling the segment.

Route of Administration Segment Analysis

Based on route of administration, the macular degeneration treatment market is divided into intravenous route and intravitreal route. The intravitreal route segment is expected to expand at a significant growth rate during the projection period, owing to the ease of drug delivery into the vitreous humor of the eye. The high efficiency and targeted treatment approach of intravitreal route is boosting the segment.  

Get Free Sample Report

Regional Analysis

In terms of region, the global macular degeneration treatment market is classified as Asia Pacific, North America, Latin America, Europe, and the Middle East & Africa. North America is expected to dominate the market during the forecast period, owing to the increasing developmental activities in this region. Furthermore, the increasing prevalence of age-related macular degradation in this region and increasing awareness for the treatment is propelling the regional market.

• In October, 2023, according to an article published by Ability Central, about 200,000 new cases of age-related macular degeneration (AMD) are diagnosed each year in North America.
  

  Get Free Sample Report